Evidence map›Paper›PMID 33876412›Full record

ArticleJournal of neurovirology2021

Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia.

S Borrelli, B Dachy, M-D Gazagnes, R Du Pasquier

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Progressive multifocal leukoencephalopathy in multiple myeloma: a case report of a patient with SARS-CoV-2 infection and an updated systematic literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

S BorrelliDepartment of Neurology, Brugmann University Hospital and Free University of Brussels (ULB), Brussels, Belgium. serena.borrelli.sb@gmail.com.ORCID 0000-0002-3186-1562
B DachyDepartment of Neurology, Brugmann University Hospital and Free University of Brussels (ULB), Brussels, Belgium.
M-D GazagnesDepartment of Neurology, Brugmann University Hospital and Free University of Brussels (ULB), Brussels, Belgium.
R Du PasquierService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Centre Hospitalier Universitaire Brugmann · BEUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive multifocal leucoencephalopathy is a serious side effect of natalizumab, a humanized monoclonal antibody approved for the treatment of multiple sclerosis. Here, we report a case of unexpected worsening of natalizumab-related progressive multifocal leucoencephalopathy following COVID-19. After natalizumab discontinuation, a slight neurological improvement was observed, but, two months later the patient was admitted to the hospital because of neurological deterioration and COVID-19 mild pneumonia. Except for SARS-CoV-2 infection, no other potential factors of neurological worsening were identified. Thus, we pose the hypothesis that SARS-CoV-2 was instrumental in the progressive multifocal leucoencephalopathy deterioration.

Indexed as

COVID-19HumansImmunologic FactorsLeukoencephalopathy, Progressive MultifocalMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNatalizumabPneumoniaSARS-CoV-2Immunologic FactorsNatalizumabCOVID-19Multiple sclerosisNatalizumabProgressive multifocal leucoencephalopathySARS-CoV-2

Identifiers

PMID33876412
PMCPMC8054855
OpenAlexW3153425243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.